Legislation Allowes Prescription Drug Reimportation
The National Federation of Independent Business has announced its endorsement of legislation (S 242 and HR 380) that would allow the purchase of lower-cost, FDA-approved drugs from other nations, CQ HealthBeat reports (CQ HealthBeat, 8/10).
Thelegislation would allow consumers, pharmacies and wholesalers topurchase FDA-approved prescription drugs that are manufactured atFDA-inspected facilities in 19 industrialized nations. Under thelegislation, which would establish a regulatory framework forreimportation, FDA would regulate shipments of prescription drugsreimported into the U.S. for commercial or personal use. The bill alsowould require FDA to inspect Canadian prescription drug exporters 12times annually (Kaiser Daily Health Policy Report, 5/8).
Inits endorsement letter, NFIB wrote that the legislation "secures aframework for the safe and legal importation of prescription drugs,"adding that it "is pleased that your legislation includes specificrequirements that ensure that every imported drug meets U.S. safetystandards." More than 50 consumer, labor and other organizations haveendorsed the bills, which would save U.S. residents an estimated $50billion over the next 10 years, according to advocates. Opponents ofthe legislation, including the Pharmaceutical Research and Manufacturers of America, claim allowing drug reimportation would open the nation's drug supply to counterfeiters (CQ HealthBeat, 8/10).
Reprinted with permission fromkaisernetwork.org.You can view the entire KaiserDaily Health Policy Report, search the archives, andsign up for email delivery at kaisernetwork.org/email. The Kaiser Daily Health Policy Report is published forkaisernetwork.org,a free service of The Henry J. Kaiser Family Foundation.